Z17.32
Human epidermal growth factor receptor 2 negative status
Clinical Classification Guidelines
Inclusion Terms
- HER2-
Medical Intelligence & Overview
HER2-negative status, classified under ICD-10 code Z17.32, refers to a specific characteristic of certain breast cancers. In this context, 'HER2' stands for human epidermal growth factor receptor 2, a protein that can influence how breast cancer grows and responds to treatment. When a tumor is HER2-negative, it means that this protein is not overproduced on the surface of the cancer cells. This classification is essential for determining the most effective treatment options and understanding the prognosis of the disease.
Causes & Symptoms
Clinical Causes: Genetic factors: Mutations in genes that influence HER2 expression. Tumor biology: Natural variation in cancer cell characteristics leading to absence of HER2 overexpression. Environmental factors: Although less established, potential influences on gene expression related to HER2 status.
Key Symptoms: Lumps or masses in the breast tissue. Changes in the size, shape, or appearance of the breast. Skin changes such as redness or dimpling over the site of the tumor. Nipple discharge or inversion. Persistent pain or discomfort in the breast or underarm region.
Diagnostic & Treatment
Diagnosis Path: The determination of HER2 status involves specific tests performed on tissue samples from a breast biopsy. These tests include:
Treatment Protocols: Treatment strategies for HER2-negative breast cancer differ from HER2-positive cases. Approaches generally include:
Clinical Advice & FAQs
Billing Guidance
Is Z17.32 a billable ICD-10 code?
Yes, Z17.32 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.32?
Clinical documentation must specify the nature of Human epidermal growth factor receptor 2 negative status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference